COVID-19 Research at Vall d’Hebron Assistance and research go hand in hand in the fight against COVID-19 at Vall d’Hebron. From the very beginning, all professionals have joined efforts to face the challenges posed by an unprecedented global epidemic, making us a reference center for COVID-19. Vall d’Hebron Research Task Force COVID-19 The Vall d’Hebron Barcelona Hospital Campus has been and continues to be a reference center for COVID-19. During the first wave of the pandemic, it was the hospital with the highest number of COVID-19 hospitalizations in Catalonia and also admitted the largest number of patients in its ICU. But it is not only a reference in healthcare, as from the outset COVID-19 research became one of the core focuses of the research groups at the Vall d’Hebron Research Institute (VHIR). A clear example of this scientific activity is the publication of more than 300 articles on COVID-19 with the participation of Vall d’Hebron professionals since the start of the pandemic. With the experience gained from these intense recent months and a commitment to continuous improvement, we have created a multidisciplinary working environment (Task Force) of over 190 researchers to provide the best possible service to the public while addressing many of the remaining challenges posed by COVID-19. These professionals belong to 28 research groups (27 from VHIR and 1 from VHIO), 31 hospital care services, a Scientific-Technical Service of VHIR (Statistics and Bioinformatics Unit), the Hospital Information Systems Directorate, and the Primary Care Center IDIAP Jordi Gol. Main objectives of the Task Force: Concentrate and coordinate the efforts of all involved professionals. Strengthen horizontal support to implement proposed initiatives and activities. Continue encouraging and facilitating the work of our researchers in publishing COVID-19 studies and achieving competitive projects (several currently underway) to increase scientific output and knowledge. In this sense, coordinating scientific efforts at the institutional level is not new. For example, hospitals belonging to the EUHA (European University Hospitals Alliance) have implemented different strategies to coordinate activities and find synergies within their scientific communities. Task Force COVID-19 Steering Committee Dr. Magda Campins Dr. Tomàs Pumarola Dr. Benito Almirante Dr. Ricard Ferrer Dr. Jaume Joan Ferrer Dr. Ricardo Pujol Dr. Josep Antoni Ramos-Quiroga Dr. Pere Soler Governance Our Research Projects and Clinical Trials Projects Whole-genome sequencing of SARS-CoV-2 in patients with mild and severe COVID-19 to identify virulence and prognosis factors Identification of repurposed drugs that inhibit the interaction between SARS-CoV-2 and ACE2 using lung organ cultures Pregnancy and COVID-19: clinical and microbiological study (GESTA-COVID19) COVID-19, immunological risk profile Prevalence of COVID-19 in patients with chronic arthritis under treatment Study on the use of personal protective equipment and surface contamination in patients with severe respiratory infection due to CORONAVIRUS 2 (SARS-CoV-2) treated with high-flow nasal oxygen therapy MSC1, a therapeutic anti-LIF antibody, as a potential treatment for COVID-19 Clinical trials Whole-genome sequencing of SARS-CoV-2 in patients with mild and severe COVID-19 to identify virulence and prognosis factors Identification of repurposed drugs that inhibit the interaction between SARS-CoV-2 and ACE2 using lung organ cultures Pregnancy and COVID-19: clinical and microbiological study (GESTA-COVID19) COVID-19, immunological risk profile Prevalence of COVID-19 in patients with chronic arthritis under treatment Study on the use of personal protective equipment and surface contamination in patients with severe respiratory infection due to CORONAVIRUS 2 (SARS-CoV-2) treated with high-flow nasal oxygen therapy MSC1, a therapeutic anti-LIF antibody, as a potential treatment for COVID-19 Clinical trials Prospective pilot, double-blind, randomised, parallel, placebo-controlled clinical trial to assess the efficacy and safety of two doses of MSC, WJ in patients with acute respiratory distress syndrome secondary to COVID-19 infection Phase III, open-label, randomised, controlled study to evaluate the efficacy and safety of intravenous ravulizumab compared with best supportive care in patients with severe pneumonia, acute lung injury or acute respiratory distress syndrome due to COVID-19 Phase 3 multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab in cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID) Multicentre, randomised, open-label, parallel-group pilot study to assess the safety and efficacy of alpha-1 protease (Prolastin®) in combination with standard medical treatment (SMT) compared with SMT alone in hospitalised subjects with COVID-19 Clinical trial of anakinra (anti-IL-1) in cytokine storm syndrome (CSS) secondary to COVID-19 Open-label phase II study to evaluate the efficacy and tolerability of vafidemstat combined with standard treatment to prevent acute respiratory distress syndrome (ARDS) in critically ill adult patients with COVID-19 Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients on parenteral nutrition and with SARS-CoV-2 respiratory infection: randomised clinical trial COVID-19 Randomised, double-blind, placebo-controlled study of gastro-resistant capsules of eicosapentaenoic acid (EPA-FFA) to treat hospitalised subjects with confirmed SARS-CoV-2 (COVID-19) lung disease TRISTARDS trial – ThRombolysIS Therapy for ARDS. Phase IIb/III, operationally optimal, open-label, randomised, sequential, parallel-group, adaptive trial to assess the efficacy and safety of daily intravenous alteplase administered for up to 5 days, in addition to standard of care (SOC), compared with SOC alone, in patients with ARDS triggered by COVID-19 Phase II, randomised, open-label, controlled study to assess the efficacy and safety of combining tocilizumab with pembrolizumab (MK-3475) in patients with pneumonia caused by coronavirus disease 2019 (COVID-19) Phase 2/3, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and pharmacokinetics of MK-4482 in adults hospitalised with COVID-19 Inhaled corticosteroids in COVID-19 patients with pneumonia Phase 3 randomised study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with moderate COVID-19 infection compared with standard of care Phase 3 randomised study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with severe COVID-19 infection Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of remdesivir plus tocilizumab versus remdesivir plus placebo in hospitalised patients with severe COVID-19 pneumonia Adaptive phase 2/3, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of sarilumab in hospitalised patients with COVID-19 Phase 2, randomised, single-blind study to assess the activity and safety of low-dose oral selinexor (KPT-330) in patients with severe COVID-19 infection Phase 3, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine release syndrome Multicentre, phase III, double-blind, randomised trial to assess the efficacy and safety of ivermectin plus standard treatment compared with placebo plus standard treatment in hospitalised patients with coronavirus disease (COVID-19) not requiring invasive ventilation Randomised, double-blind, placebo-controlled, multicentre study to assess the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia More than 190 professionals involved in this project have been organised into 22 multidisciplinary subgroups, each focusing on a specific aspect of COVID-19. These are divided into blocks according to the type of research they conduct. Below we present each group and the main research areas in which they will focus their work: Block A: Molecular / Cellular / Mechanistic Immunological risk profile in COVID-19 Research lines Immunological risk profile in COVID-19 Haemophagocytic lymphohistiocytosis (HLH) in COVID-19 T-cell response against SARS-CoV-2 Role of mast cells in the pathophysiology of COVID-19 Participation in the international COVIDHGE consortium LIF as a potential therapeutic target against COVID-19 Role of cytokine haemadsorption as a rescue treatment in severe forms of COVID-19 Group leader Hernández González, Manuel Principal investigators Hernández González, Manuel Martínez Gallo, Mónica Seoane Suarez, Joan Colobran Oriol, Roger Ruiz Rodriguez, Juan Carlos Ramon y Cajal Agüeras, Santiago Soler Palacín, Pere Martín Nalda, Andrea Rivière, Jacques Esperalba Esquerra, Juliana Pujol Borrell, Ricardo Sanchez Montalvá, Adrián Labrador Horrillo, Moisés Gene and cell therapy: development of a hybrid preventive vaccine (genetic and protein-based) using modified AAV vectors Research lines Development of a hybrid preventive vaccine (genetic and protein-based) using modified AAV vectors The group has experience in the design and use of viral vectors for different therapeutic applications, which we believe could serve as a platform for creating new hybrid preventive vaccines (genetic and protein-based), in this case against COVID-19 Group leader Barquinero Mañez, Jordi Principal investigators Barquinero Mañez, Jordi Chillon Rodriguez, Miguel Anguela Martínez, Xavier Host–pathogen interactions Research lines Identification of SARS-CoV-2 target cells and entry receptors in the human lung (which could extend to other primary cells or tissues) Effect of local conditions and immune mediators (i.e., IFN, IL-6, IL-1b, TNFα, etc.) on receptor expression and SARS-CoV-2 entry Identification of therapeutic agents to inhibit SARS-CoV-2 interaction/entry in the human lung (and possibly other primary cells or tissues) Identification of immune correlates of protection in individuals with mild infection (neutralising antibodies, ADE, tissue-resident T-cell memory) Group leader Buzón Gómez, Mª José Principal investigators Buzón Gómez, Mª José Genescà Ferrer, Meritxell Chillón Rodríguez, Miguel Jauregui Abularach, Alberto Rosado Rodríguez, Joel Soler Romero, Mª José Renin–angiotensin–aldosterone system in COVID-19 Research lines Analysis of the RAAS pathway status in patients with COVID-19 Study of the influence of ACE inhibitors/ARBs on ACE2 expression in different tissues (kidney, lung, heart) in humans, animal models and cell models Group leader Soler Romeo, Maria Jose Principal investigators Soler Romeo, Maria Jose Jacobs Cachá, Concepció Serón Micas, Daniel Trilla Herrera, Enric Rosado Rodríguez, Joel Genesca Ferrer, Meritxell Buzón Gómez, María José Ribera Sole, Aida Benito Villabriga, Begoña Hernández González, Manuel Ferrer Costa, Roser Rodríguez Frías, Francisco Gabriel Medina, Pablo Román Broto, Antonio Block B: Global care SARS-CoV-2: microbiological diagnosis, seroprevalence of infection, genetic characterisation and evolution, and vaccine Research lines Molecular epidemiology, surveillance and outbreak monitoring of SARS-CoV-2 (Dr Andrés Antón) SARS-CoV-2 variability (Dr Josep Quer) Seroprevalence of SARS-CoV-2 infection in Catalonia (Dr Juliana Esperalba) VLP-based vaccine against SARS-CoV-2 (Dr Joan Joseph / Dr Narcís Saubí) Group leader Antón Pagarolas, Andres Principal investigators Antón Pagarolas, Andres Pumarola Suñé, Tomàs Quer Sivila, Josep Esperalba Esquerra, Juliana Sulleiro Igual, Elena Rando Segura, Ariadna Joseph Munné, Joan Andrés Vargés, Cristina Rodríguez Frias, Francisco Cortese, Maria Francesca Saubí Roca, Narcís Piñana Moro, Maria Silgado Gimenez, Aroa Fernandez Naval, Candela Guerrero Murillo, Mercedes Garcia Cehic, Damir SARS-CoV-2 infection in patients Research lines Factors associated with patients’ clinical evolution, including modifiable and non-modifiable factors. Among the modifiable factors, we will study pharmacological and non-pharmacological interventions Long-term complications. The acquisition of early and lasting immunity after natural or artificial exposure is of vital importance for disease dynamics at community level Group leader Sánchez Montalvá, Adrián Principal investigators Sánchez Montalvá, Adrián Fernández Hidalgo, Nuria Burgos Cibrian, Joaquin Espinosa Pereiro, Juan Salvador Velez, Fernando M Pujol Borrell, Ricardo Antón Pagarolas, Andres Clinical pharmacology of the VH COVID-19 TASK FORCE Research lines Treatment with hydroxychloroquine is associated with faster PCR negativisation and greater symptom improvement in hospital staff with mild infection (without initial hospitalisation criteria) due to COVID-19 Severity of COVID-19 patients is associated with outpatient treatment with drugs that may worsen the disease through mechanisms other than the ACE2 receptor Incidence, types and severity of adverse drug reactions (ADRs) in hospitalised patients during the pandemic International collaborative COVID-19 cohort network for optimal treatment and prevention, Horizon2020 call (H2020-SC1-PHE-Coronavirus-2020-2), proposal number 1010115994, acronym: CONNECTION COVID-19 infection and medicines during pregnancy (CONSIGN), proposal from the EU PE & PV Research Network under a framework contract following EMA procurement procedure EMA/2017/09/PE/11 (lot 4). Study on the impact of COVID-19 infection and medicines during pregnancy Group leader Agustí Escasany, Maria Antònia Principal investigators Agustí Escasany, Maria Antònia Diogène Fadini, Eduard Danes Carreras, Immaculada Vidal Guitart, Xavier Sabaté Gallego, Mònica Aguilera Martin, Cristina Ballarin Alins, Maria Elena Riera Arnau, Judit Ribera Pascuet, Esteve Sánchez Montalvá, Adrián Cossio Gil, Yolima Aller Hernández, Marta Beatriz Gorgas Torner, Maria Queralt Miarons Font, Marta Far Ruíz, Marc Aragón, Maria Epidemiology and prevention of SARS-CoV-2 infection. Vaccines against SARS-CoV-2 Research lines Prevention of infection through safe, effective and efficient vaccines and prophylactic drugs against SARS-CoV-2 infection Epidemiology of SARS-CoV-2 and transmission dynamics in vulnerable populations (care homes for the elderly, institutionalised populations, healthcare workers) Group leader Otero Romero, Susana Principal investigators Otero Romero, Susana Martínez Gómez, Xavier Rodrigo Pendás, Jose Angel Uriona Tuma, Sonia Maria Borras Bermejo, Blanca Campins Martí, Magda Llorente Parrado, Cesar Esperalba Esquerra, Juliana Antón Pagarolas, Andres Soriano Arandes, Antoni Melendo Perez, Susana Almirante Gragera, Benito Management, complications and sequelae in critically ill patients with COVID-19 Research lines Study of environmental contamination of surfaces and personal protective equipment in patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2) treated with high-flow nasal cannula oxygen therapy. Study of the incidence of superinfections in patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2). Study of the long-term morpho-functional alterations in patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2) meeting criteria for severe acute respiratory distress syndrome. Effect of inhaled nitric oxide therapy in patients with respiratory infection due to coronavirus 2 (SARS-CoV-2) meeting criteria for severe acute respiratory distress syndrome. Analysis of the immunological profile of patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2) meeting criteria for acute respiratory distress syndrome. Analysis of pregnant patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2) compared with non-pregnant patients with the same condition. Analysis of the clinical profile of paediatric patients with severe respiratory infection due to coronavirus 2 (SARS-CoV-2). Group leader Oriol Roca Principal investigators Roca, Oriol Ferrer, Ricard Ruiz, Juan Carlos Nuvials, Xavier Cruz, Maria Jesús Muñoz, Xavier Rodríguez, Virginia Antón, Andrés Martínez, Mònica Pujol, Ricardo Balcells, Joan Suy, Anna Pacheco, Andrés García-de-Acilu, Marina Ramos, Francisco J. Martínez, María Phenotypes and precision medicine Research lines Precision medicine requires the identification of different phenotypes and biomarkers to allow individualisation of treatments and comparison of disease progression and complications. Research questions focus on clarifying the interaction between the virus and the host. The group has contributed to the identification of phenotypes and raises research questions on biomarkers in different subpopulations and in database analyses. The identification of different biomarkers allows characterisation of these phenotypes, prognostic stratification, and comparisons with other viruses (RSV, influenza virus, etc.). This research line is patient-centred and covers the outpatient, hospitalisation, ICU and post-COVID follow-up phases. Group leader Jordi Rello Condomines Principal investigators Rello Condomines, Jordi Balcells Ramirez, Joan Mazo Torre, Cristopher Alan Peña Lopez, Yolanda Pont Castellana, Teresa Sandiumenge Camps, Alberto Tejada Magraner, Sofia < 1 2 > Block C: COVID-19 in relation to specific themes Impact of COVID-19 on solid organ transplantation Research lines Investigation of the effect of COVID-19 infection in solid organ transplant (SOT) recipients. SOT recipients (kidney, lung, liver) share, in addition to immunosuppression, other features that make them a population with unique characteristics. Group leader Manuel López Meseguer Principal investigators López Meseguer, Manuel Campos Varela, Isabel Moreso Mateos, Francesc Esperalba Esquerra, Juliana Gómez Olles, Susana COVID-19 research in paediatrics Research lines Study of SARS-CoV-2 transmissibility in paediatric patients (CO-PEDIA-CAT study). Utility of treatments against SARS-CoV-2 in paediatrics. Study of multisystem inflammatory syndrome associated with COVID-19 in paediatrics. Mother-to-child transmission of COVID-19 (together with Obstetrics groups). Group leader Antoni Soriano Arandes Principal investigators Soriano Arandes, Antoni Melendo Perez, Susana Martín Nalda, Andrea Frick , Marie Antoinette Rivière, Jacques Soler Palacín, Pere Campins Martí, Magda Otero Romero, Susana Esperalba Esquerra, Juliana Sulleiro Igual, Elena Antón Pagarolas, Andres Colobran Oriol, Roger Suy Franch, Anna Camba Longueira, Fátima Wörner Tomasa, Núria Casquero Cossío, Alejandro Rodríguez Losada, Olalla González Peris, Sebastià Velasco Puyó, Pablo ECMO (extracorporeal membrane oxygenation) Research lines During the pandemic, ECMO has been shown to rescue patients with hypoxaemia and/or shock refractory to conventional supportive measures. Group leader Jordi Riera del Brío Principal investigators Riera del Brío, Jordi Argudo Serra, Eduard Martinez Martinez, Maria Diaz Lagares, Candido Contreras Medina, Sofia García Roche, Sandra Rodríguez Lecoq, Rafael Castro Alba, Miguel Angel COVID-19 and neuromuscular disease Research lines Investigation of the onset of neuromuscular diseases secondary to infection of the peripheral nervous system by the virus and the immune response against the virus (e.g. post-COVID Guillain-Barré syndrome and Miller Fisher syndrome). Study of exacerbations of pre-existing neuromuscular diseases such as myasthenia gravis, amyotrophic lateral sclerosis and other myopathies. Identification of the consequences of COVID-19 treatments in patients with neuromuscular diseases or other patients with prolonged ICU stays (critical illness neuromyopathy). Study of the impact on clinical management of neuromuscular unit patients due to disruptions in healthcare system functioning (issues with hospital access for proper follow-up, diagnostic delays of neuromuscular diseases). Identification of genetic susceptibility factors predisposing to the development of neuromuscular diseases associated with SARS-CoV-2 infection. Study of how lockdown situations have a psychological impact that alters the quality of life of people affected by neuromuscular disease. Group leader Raul Juntas Morales Principal investigators Juntas Morales, Raul González Martínez, María Victoria Palasi Franco, Antonio Sánchez-Tejerin San José, Daniel Salvadó Figueras, Maria Vidal Taboada, José Manuel Canovas Segura, Anna Belen Cardiology within the VH Task Force on COVID-19 Research lines Effect of renin–angiotensin system inhibitor drugs on COVID-19 infection in patients with cardiovascular disease, diabetes or hypertension. Impact of the COVID-19 pandemic on the care of patients with cardiovascular disease: current dynamics and future projections (IMPACAR). Influence of SARS-CoV-2 infection on the development of cardiac arrhythmias in patients with structural heart disease carrying implantable cardiac devices. One-year cardiovascular impact of COVID-19 infection. The aim is to conduct a one-year follow-up and record cardiovascular clinical events in this population. Morphological cardiac involvement in COVID-19 infection characterised using echocardiography with strain and cardiac magnetic resonance imaging. Long-term myocardial fibrosis in patients with COVID-19. Calpain inhibition as an antifibrotic strategy. ACE-2 receptors play a key role in the pathogenesis of the virus. Disruption of this receptor leads, in the long term, to cardiac remodelling involving hypertrophy and fibrosis, cardiac dysfunction and heart failure. New calpain inhibitors prevent fibroblast activation and interstitial collagen deposition, and improve ventricular function in experimental models of ACE-2 activation. Therapeutic strategies to reduce cardiac injury secondary to the inflammatory cytokine storm in COVID-19. Group leader Jordi Bañeras Rius Principal investigators Bañeras Rius, Jordi Clau-Terré, Fernando García García de Acilu, Marina Cossio Gil, Yolima Aller Hernández, Marta Beatriz Soler Romeo, Maria José Ribera Sole, Aida Rivas Gandara, Nuria Inserte Igual, Javier Rodríguez Sinovas, Antonio Rodríguez Palomares, Jose Fernando Ferreira González, Ignacio Maternal–fetal medicine research group / COVID-19 and pregnancy Research lines Impact of SARS-CoV-2 infection in pregnant women. Foetal impact of SARS-CoV-2 infection during pregnancy. Vertical transmission of SARS-CoV-2 infection. Group leader Anna Suy Franch Principal investigators Suy Franch, Anna Maiz Elizaran, Nerea Garcia Ruiz de Gordejuela, Itziar Rodó Rodríguez, Carlota Fernández Hidalgo, Núria Sacanell Lacasa, Judith Balcells Ramirez, Joan Sulleiro Igual, Elena Navarro Jiménez, Alexandra Ribes Bautista, Carmen Frick, Marie Antoinette Campins Martí, Magda Impact of COVID-19 sequelae Research lines Influence of fatigue and muscle dysfunction in patients with COVID-19 and functional capacity. Effectiveness of early mobilisation in reducing complications from ICU admission in patients with COVID-19. Impact of physical inactivity on comorbidity in wheelchair users during the pandemic. Effects of a mobile health (mHealth) intervention on physical inactivity in patients with spinal cord injury during the COVID-19 pandemic. Neurological complications in patients with severe COVID-19 pneumonia and neurorehabilitation approaches. Prevalence study of sequelae related to dysphagia and voice in patients hospitalised for COVID-19 pneumonia. Medium-term telematic follow-up programme after hospital discharge for patient functional assessment. Impact of the high-resolution consultation on the assessment of post-COVID sequelae. PROMs and PREMs after treatment with the ReHab platform in patients with motor and respiratory sequelae following COVID-19. Group leader Lluïsa Montesinos Principal investigators Gómez Garrido, Alba Montesinos Magraner, Lluïsa Rodríguez González, Susana Velasco Zarzuelo, Mercedes Crespo Fresno, Almudena Sánchez Raya, Judith < 1 2 > Block D: Cross-cutting themes Governance, standardisation and data analysis Research lines Data governance. Standardisation and integration of databases. Data exploitation. Group leader Àlex Sánchez Pla Principal investigators Sánchez Pla, Àlex Mota Foix, Miriam Pérez Hoyos, Santi Molecular medical imaging (clinical and preclinical) and metabolomics Research lines Molecular medical imaging studies (clinical – based on PET/CT or SPECT/CT – and preclinical in any imaging discipline) and metabolomics of any type of sample (plasma, serum, peripheral blood cells (RBC, PBMC, PMN…), tissues, faeces, etc.) in order to: Find new diagnostic approaches (either 100% imaging-based or through artificial intelligence). Identify new diagnostic biomarkers. Discover new therapeutic targets. Study the effects of the virus on the physiology and metabolism of certain organs or tissues. Group leader José Raul Herance Camacho Principal investigators Herance Camacho, José Raul Castell Conesa, Joan Aguade Bruix, Santiago Baguña Torres, Julia Xiao, Xingpeng Aparicio Gomez, Carolina Ferrer Costa, Roser Giralt Arnaiz, Marina Mental health and COVID-19 clinical and functional impact of the disease and prevention Research lines Impact of COVID-19 on mental disorders. Mental disorders as a risk factor for COVID-19 immunological profile. COVID-19 mental health impact on professionals. End-of-life processes. Evolution of mental health in patients with COVID-19. Group leaders Ana Beneria / Mireia Forner Principal investigators Beneria González, Ana Fidel Kinori, Sara Guila Forner Puntonet, Mireia Gisbert Gustemps, Laura Lugo Marín, Jorge Inzitari, Marco Biological samples Research lines Processing of biological samples. Access to biological samples. Biosafety in sample handling. Group leader Isabel Novoa Principal investigators Hernández González, Manuel Roger Colobran Oriol Cruz, Mª Jesús Antón, Andrés Esperalba, Juliana Block E: Looking for collaboration Study on the incidence of SARS-CoV-2 (COVID-19) infection in patients with multiple sclerosis or other phenotypes (optic neuromyelitis and MOG) Research lines Study on the incidence of SARS-CoV-2 (COVID-19) infection in patients with multiple sclerosis or other phenotypes (optic neuromyelitis and MOG). Group leader Xavier Montalbán Principal investigators Montalbán, Xavier Arrambide, Georgina Zabalza, Ana
